Revance Therapeutics CEO Mark Foley receives $17M in 2019
Revance Therapeutics reports 2019 executive compensation
By ExecPay News
Published: March 26, 2020
Revance Therapeutics reported fiscal year 2019 executive compensation information on March 26, 2020.
In 2019, six executives at Revance Therapeutics received on average a compensation package of $4.5M, a 108% increase compared to previous year.
Average pay of disclosed executives at Revance Therapeutics
Mark J. Foley, Chief Executive Officer, received $17M in total. 68% of Foley's compensation, or $12M, was in stock awards. Foley also received $150K in bonus, $5.1M in option awards, $190K in salary, as well as $9.7K in other compensation.
L. Daniel Browne, Chief Executive Officer, received a compensation package of $4.9M, which increased by 5% compared to previous year. 60% of the compensation package, or $2.9M, was in option awards.
Abhay Joshi, Chief Operating Officer, earned $1.9M in 2019, a 15% decrease compared to previous year.
Caryn G. McDowell, General Counsel, received $1.2M in 2019, which decreases by 54% compared to 2018.
Tobin C. Schilke, Chief Financial Officer, earned $1M in 2019, a 49% decrease compared to previous year.
Dustin Sjuts, Chief Commercial Officer, received $801K in 2019.
Related executives
Mark Foley
Revance Therapeutics
Chief Executive Officer
L Browne
Revance Therapeutics
Chief Executive Officer
Tobin Schilke
Revance Therapeutics
Chief Financial Officer
Abhay Joshi
Revance Therapeutics
Chief Operating Officer
Dustin Sjuts
Revance Therapeutics
President
Caryn McDowell
Revance Therapeutics
General Counsel
You may also like
Source: SEC filing on March 26, 2020.